Best Chocolate Weight Loss Supplement: Consumer Analysis Examines Cacao GLP-1 Research as January Wellness Interest Surges

Best Chocolate Weight Loss Supplement: Consumer Analysis Examines Cacao GLP-1 Research as January Wellness Interest Surges




Best Chocolate Weight Loss Supplement: Consumer Analysis Examines Cacao GLP-1 Research as January Wellness Interest Surges

Consumer analysis evaluates Earth Echo Cacao Bliss ingredient disclosures, ceremonial-grade processing claims, and published GLP-1 research frequently referenced in chocolate-based weight management supplement discussions as January wellness searches surge; this report does not provide medical advice or guarantee individual outcomes.

BOULDER, CO, Jan. 02, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Always consult a qualified healthcare professional before starting supplements. If you purchase through links in this article, a commission may be earned at no additional cost to you.

As early January begins, search interest often rises across weight-management topics, reflecting seasonal consumer attention and renewed focus on wellness goals. This consumer analysis examines how chocolate-based supplement positioning intersects three simultaneous market factors: published research documenting cacao’s influence on satiety mechanisms, predictable New Year wellness commitment patterns, and growing consumer awareness of GLP-1 hormone pathways following mainstream pharmaceutical coverage.

This analysis specifically summarizes how Earth Echo Foods positions its Cacao Bliss ceremonial-grade formulation within this context, providing consumers with a summary of publicly available ingredient disclosures, processing method claims, and research context frequently referenced in chocolate-based metabolic support supplement discussions.

Best Chocolate Weight Loss Supplement Consumer Analysis Examines Cacao GLP-1 Research as January Wellness Interest Surges

What This Analysis Provides:

This report systematically summarizes Earth Echo Foods’ publicly available ingredient disclosures, examines the research context often cited in chocolate weight loss supplement discussions, provides a safety framework based on published ingredient information, and outlines common questions consumers consider when evaluating supplement fit. This is a summary of publicly available information—not product endorsement or independent verification of efficacy claims.

Readers who want to review the company’s current product description and posted terms can view Earth Echo Foods’ official Cacao Bliss product page.

What “Best Chocolate Weight Loss Supplement” Actually Means in 2026 (And What It Doesn’t)

When consumers search for “best chocolate weight loss supplement” following advertisement exposure or social media content, they’re typically asking three distinct questions: Is there legitimate research supporting chocolate for weight management? How do I differentiate quality formulations from inferior products? Which specific product aligns with my individual needs and circumstances?

Understanding what “best” actually means requires establishing evaluation criteria rather than declaring winners. This analysis does not determine which product is objectively “best” as individual needs, preferences, metabolic responses, and health circumstances vary dramatically across consumers. Instead, this section establishes the framework readers can use to conduct their own evaluations.

Category Definition: What Makes a Chocolate Supplement Different From Conventional Chocolate

The fundamental distinction consumers must understand: chocolate-based weight management supplements represent a specific product category that differs substantially from conventional chocolate products purchased in grocery stores. The differentiation centers on processing methods, ingredient purity, bioactive compound preservation, and formulation strategy.

According to research published in The Journal of Agricultural and Food Chemistry, conventional chocolate processing—including high-temperature roasting (often 300-450°F) and alkaline treatment called Dutching—reduces antioxidant content substantially compared to minimally processed cacao. This processing degradation explains why eating conventional milk chocolate doesn’t produce the metabolic outcomes observed in research studies using minimally processed cacao.

The term “ceremonial-grade cacao” references traditional preparation methods used in Central and South American cultures, where cacao beans undergo sun-drying and minimal processing to preserve naturally occurring compounds. Modern supplement formulations using ceremonial-grade positioning claim to maintain these bioactive compounds through temperature-controlled processing rather than high-heat industrial methods.

Evaluation Criteria for Comparing Chocolate-Based Supplements

Consumers evaluating options in this category should verify the following information from company sources:

Processing Method Transparency: Does the company disclose whether cacao is roasted at high temperatures or processed using low-heat methods? Is alkaline treatment (Dutching) used? Temperature and pH manipulation directly impact compound preservation.

Ingredient Disclosure Standards: Does the company list specific ingredient amounts or hide formulation details behind “proprietary blend” language? Proprietary blends prevent consumers from comparing dosages or evaluating adequacy against research contexts.

Third-Party Testing Verification: Does the company provide documentation of third-party testing for purity, potency, and contaminant screening? Quality manufacturers invest in independent verification.

Company Legitimacy Indicators: Can consumers easily find contact information including phone numbers, email addresses, and physical headquarters locations? Are return policies clearly stated with adequate evaluation windows? Legitimate companies provide transparent communication channels.

Research Context Alignment: When companies reference research studies, can consumers verify those studies exist through independent searches? Are study details accurately represented or selectively presented?

These criteria provide a methodology for evaluation across any product in this category, not just Earth Echo Foods’ Cacao Bliss specifically.

Why January 2026 Search Volume Patterns Create Heightened Consumer Interest

Understanding seasonal search behavior provides context for current market attention on chocolate-based weight management supplements and the timing of this analysis. According to recurring patterns observable in public trend tools, weight loss-related search terms often show elevated interest during the first weeks of January compared to late-year baseline periods.

This surge reflects several psychological and cultural factors: New Year resolution commitment psychology creates temporary motivation enhancement as individuals set fresh goals following the symbolic January 1st temporal landmark. Post-holiday awareness develops after approximately two months of seasonal indulgence (Thanksgiving through New Year’s), creating desire for course correction. Increased health consciousness emerges as individuals reflect on aging, mortality, and wellness priorities during year-end periods.

The GLP-1 Cultural Moment

A significant factor influencing current chocolate weight loss supplement interest involves widespread consumer awareness of GLP-1 hormone function, driven by prescription GLP-1 medication coverage in mainstream media. Pharmaceutical interventions that work by mimicking GLP-1’s appetite suppression effects have received extensive discussion, educating consumers about this satiety hormone pathway.

This pharmaceutical awareness creates consumer curiosity about whether dietary approaches can support natural GLP-1 production at meaningful levels—a question that published research has begun examining. The appeal of “chocolate instead of injections” messaging capitalizes on this cultural moment where consumers understand GLP-1’s function but seek alternatives to prescription interventions.

Consumer Sophistication About Processing Quality

Another relevant trend involves increasing consumer attention to ingredient sourcing and processing method differentiation. Modern consumers demonstrate growing skepticism toward generic supplement positioning and increasingly seek verification of quality claims through processing transparency, sourcing documentation, and third-party testing confirmation.

This sophistication benefits companies investing in premium processing methods and transparent disclosure, as educated consumers can differentiate between conventional cocoa powder marketed as premium versus genuinely preserved ceremonial-grade formulations.

Earth Echo Cacao Bliss: What the Company Discloses About Formulation and Positioning

According to publicly available materials from Earth Echo Foods, Cacao Bliss represents a specific formulation strategy: ceremonial-grade cacao combined with seven additional ingredients positioned for synergistic metabolic support, marketed as a chocolate drink mix that may naturally support satiety hormone function when consumed as part of comprehensive wellness programs.

Founder Background and Company Positioning

Earth Echo Foods was founded by Danette May, whose publicly stated credentials include celebrity fitness trainer with 20+ years professional experience, published author of two books on health and wellness, founder of the Rise Movement wellness community, and social media presence across platforms. According to company materials, May has been featured on Access Hollywood, CBS, and Hallmark programming.

The company’s founding narrative, as presented in marketing materials, describes May’s exposure to traditional ceremonial cacao preparation during travels to Costa Rica’s blue zone region—geographic areas recognized by longevity research for unusually high centenarian populations and extended health spans. This experience reportedly inspired formulation development combining ceremonial-grade cacao with researched metabolic support compounds.

Marketing Context and Viral Attention

According to Earth Echo Foods’ marketing materials, social media content demonstrating ceremonial-grade cacao preparation and explaining GLP-1 research context generated significant consumer interest and heightened search volume for chocolate-based weight management information. The positioning capitalizes on consumer desire for natural approaches to appetite management that don’t feel restrictive or punishment-based.

Product Composition Framework

According to Earth Echo Foods’ ingredient disclosure, Cacao Bliss combines eight components:

Primary Ingredient—Ceremonial-Grade Cacao: The company states the formulation uses sun-dried cacao rather than high-heat roasted processing. According to product materials, this processing method is positioned as preserving the cacao’s naturally high antioxidant capacity. The company references ORAC (Oxygen Radical Absorbance Capacity) measurement standards in comparing antioxidant content, though specific numbers should be verified on current product labels.

Supporting Ingredient Framework:

According to company ingredient disclosures:

Organic Cinnamon: Included for blood sugar stabilization properties documented in published research. Studies from institutions including Cairo University have examined cinnamon’s influence on glucose metabolism in controlled settings.

Organic Turmeric: Positioned for anti-inflammatory properties. Research from institutions including the State University of New York School of Medicine has explored curcumin compounds’ potential influence on adipose tissue inflammation markers.

Organic Piperine (Black Pepper Extract): Included specifically to address turmeric’s well-documented bioavailability limitation. Published research demonstrates piperine increases curcumin absorption substantially, addressing a known challenge with turmeric supplementation.

Organic MCT Oil (Medium-Chain Triglycerides): Positioned for satiety hormone support. Research from institutions including Columbia University has examined MCT oil’s influence on leptin and fullness signaling.

Organic Monk Fruit Powder: Zero-calorie natural sweetener that does not trigger blood sugar elevation according to metabolic research, allowing chocolate flavor satisfaction without processed sugar content.

Organic Lucuma: Peruvian fruit providing caramel-like flavor while supporting digestive function according to traditional use documentation.

Himalayan Sea Salt: Mineral content component containing multiple trace elements according to mineral composition analysis.

Nutritional Profile: According to the company’s published nutrition label, each serving contains 35 calories with zero processed sugar content.

Important Product Category Context: Cacao Bliss is classified as a dietary supplement, not a medication. This classification carries specific regulatory implications. Dietary supplements are not reviewed or approved by the FDA as finished products before market availability. The FDA requires that supplements contain what labels claim and are free from contaminants, but does not evaluate whether marketing claims are substantiated or whether products are effective for stated purposes.

The legally required disclaimer: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

Ingredient Disclosure Review: What Research Says About Ceremonial Cacao and Metabolic Support Compounds

Understanding the research context surrounding chocolate-based supplements requires examining what published studies actually tested versus what they didn’t test. This distinction helps consumers evaluate marketing claims against evidence standards.

The Ceremonial-Grade Processing Distinction

The fundamental premise underlying ceremonial-grade cacao positioning centers on bioactive compound preservation through processing method selection. This concept has research foundation examining how temperature, pH manipulation, and processing duration affect cacao’s naturally occurring compounds.

Research published in The Journal of Agricultural and Food Chemistry documented that conventional chocolate manufacturing reduces antioxidant content substantially compared to minimally processed cacao. The study examined the progressive compound degradation that occurs through each processing stage: high-temperature roasting destroys heat-sensitive flavanols, alkaline treatment (Dutching) with potassium carbonate reduces polyphenol content, extended conching at elevated temperatures further degrades bioactive compounds.

According to research examining this progressive degradation, conventional chocolate manufacturing reduces antioxidant content substantially compared to minimally processed cacao. The study examined how each processing stage progressively affects bioactive compound profiles.

This processing research provides context for why ceremonial-grade positioning emphasizes sun-drying and low-heat methods—the goal involves preserving compounds that conventional manufacturing reduces. However, consumers should note: research examines processing methods and compound preservation generally, not specific commercial products’ efficacy.

Blood Sugar Stabilization: The Cinnamon Research Context

Multiple published studies have examined cinnamon’s influence on glucose metabolism. Research from Cairo University involving 60 participants demonstrated that daily cinnamon supplementation for one month correlated with fasting blood sugar changes in the study population. Participants’ average fasting glucose levels decreased from approximately 254 mg/dL to 126 mg/dL over the study period.

Important context: This research examines cinnamon supplementation in controlled settings with specific populations and dosages. The study does not evaluate commercial products containing cinnamon as one ingredient among several, and individual responses vary based on baseline insulin sensitivity, overall dietary patterns, medication use, and numerous other metabolic factors.

Blood sugar stability relates to weight management through multiple pathways: stable glucose levels reduce reactive hunger and carbohydrate cravings, improved insulin sensitivity affects fat storage patterns, reduced blood sugar variability decreases stress hormone release that promotes abdominal fat accumulation.

Anti-Inflammatory Compounds: The Turmeric and Piperine Combination

Research from the State University of New York School of Medicine and other institutions has explored curcumin’s potential influence on inflammatory pathways in adipose tissue. Some studies following individuals who had experienced weight loss plateaus reported changes in body composition over study periods with twice-daily turmeric supplementation, though these studies examined isolated turmeric compounds rather than comprehensive formulations.

The inclusion of piperine (black pepper extract) addresses a well-documented scientific challenge: curcumin has poor bioavailability when consumed alone. Published research demonstrates piperine increases curcumin absorption by up to 2,000%, which explains why quality formulations include this combination rather than turmeric in isolation.

Satiety Hormone Support: The MCT Oil Research

Research from institutions including Columbia University has examined medium-chain triglycerides’ influence on satiety hormone signaling, particularly leptin—the hormone that signals fullness to the brain. Studies from King’s College London found that MCT oil consumption correlated with reduced overall caloric intake in controlled research settings.

The proposed mechanism involves MCT oil’s unique metabolic pathway: unlike long-chain fatty acids that require extensive digestion, medium-chain triglycerides absorb rapidly and may influence hormone signaling more directly. However, research contexts differ from real-world supplement use in dosage, timing, overall dietary composition, and individual metabolic variability.

Critical Research-to-Product Translation Context

Every research citation above shares a common limitation: studies examine isolated ingredients under controlled conditions with specific dosages, selected participant populations, and defined protocols. Commercial product use involves multiple ingredients consumed simultaneously with potential interactions, uncontrolled real-world conditions with variable diet quality and activity levels, diverse individual metabolic responses based on age and hormones and medications and genetics, inconsistent usage patterns as daily compliance varies widely, and indefinite timeframes while research studies last weeks to months.

This gap doesn’t invalidate research relevance—it explains why individual results differ from study averages and why some consumers report substantial benefits while others experience minimal effects despite identical product use.

The GLP-1 Research Context: What Studies Actually Tested vs. What They Didn’t

The GLP-1 research represents perhaps the most frequently cited evidence in chocolate weight loss supplement marketing, and it warrants detailed examination to help consumers understand what was actually demonstrated versus what remains unproven.

Understanding GLP-1 Hormone Function

GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces when you eat. It performs several metabolic functions: signals satiety (fullness) to the brain, slows gastric emptying so food stays in your stomach longer, reduces appetite and food-seeking behavior, improves insulin sensitivity, and supports healthy blood sugar regulation.

Prescription GLP-1 medications work by mimicking this hormone at therapeutic doses, creating pronounced appetite suppression effects that facilitate significant weight loss in clinical trials. These medications represent a different mechanism and magnitude than dietary approaches to supporting natural GLP-1 production.

The 2020 Nutrition Journal Study: What Was Actually Tested

The frequently referenced research appeared in the journal Nutrition in 2020. The study methodology involved 48 participants separated into two groups—one consuming water, another consuming a cacao-based beverage. Following a standardized glucose tolerance test (where participants consumed 50 grams of glucose), researchers measured GLP-1 hormone levels at intervals.

Results: Two hours post-consumption, the cacao group demonstrated nearly double the GLP-1 levels compared to the water control group. This relative change was observed under short-term laboratory conditions and does not establish clinical significance, durability, or applicability to commercial supplement use.

Significance: The study demonstrates that dietary compounds may naturally influence the same satiety hormone targeted by prescription GLP-1 medications, though the mechanisms and magnitude differ substantially from pharmaceutical interventions.

What This Study Did NOT Test

Critical limitations consumers must understand:

It Did Not Test Commercial Products: The research examined a cacao-based beverage prepared for research purposes with controlled cacao content, not finished commercial supplements like Cacao Bliss or any other branded product. Study findings cannot be directly attributed to specific products without separate testing.

It Did Not Measure Weight Loss Outcomes: The study measured hormone response over hours, not weight changes over weeks or months. GLP-1 influence is theoretically relevant to weight management, but this study didn’t track whether participants lost weight.

It Did Not Establish Effective Dosing: The study used specific cacao amounts under controlled conditions. The optimal dosage, timing, frequency, and duration for weight management outcomes remain unclear.

It Did Not Evaluate Long-Term Responses: Hormone measurements occurred during a single session. Whether daily cacao consumption maintains similar GLP-1 effects over months, whether the body adapts and diminishes response, or whether effects accumulate favorably all remain unknown.

It Did Not Compare to Pharmaceutical Magnitude: While GLP-1 levels nearly doubled, the absolute magnitude remains substantially lower than prescription GLP-1 medication effects. The clinical significance of dietary GLP-1 enhancement versus synthetic hormone delivery differs considerably.

The UC San Diego Weight Loss Research Context

Two additional studies from the University of California San Diego School of Medicine examined weight loss outcomes with cacao consumption, providing different context than the GLP-1 hormone study:

Study 1: Twenty-four overweight participants consumed cacao cookies twice daily (before breakfast and dinner) alongside light exercise protocols. After eight weeks, researchers reported average weight reduction of approximately 7 pounds and waist circumference decrease of 1.5 inches in the study population.

Study 2: Fifteen participants followed similar protocols over four weeks, with researchers reporting average weight loss of 5.3 pounds and waist reduction of 1.4 inches. Participants also reported quality-of-life improvements including better mobility, improved cholesterol markers, and lower anxiety/depression scores.

Critical Context for Both Studies:

These studies examined minimally processed cacao consumption as part of comprehensive protocols including exercise components, not cacao supplementation in isolation. Participants followed structured approaches with regular monitoring—conditions that differ substantially from independent supplement use without professional guidance or accountability structures.

The studies demonstrate that cacao consumption within comprehensive wellness programs correlated with weight loss in research populations, but they cannot establish whether cacao specifically caused the outcomes, whether exercise was the primary driver, whether accountability and monitoring influenced results more than ingredients, or whether similar outcomes would occur with unstructured supplement use.

The Honest Assessment for Consumers

Based on available research, what can consumers reasonably conclude?

Published evidence supports that cacao consumption influences GLP-1 hormone response and that minimally processed cacao consumption within structured wellness programs correlates with weight loss outcomes in research populations. The bioactive compounds in cacao (flavanols, theobromine, others) have documented effects on metabolic pathways, blood sugar regulation, and satiety signaling.

However, research does not demonstrate that drinking a commercial chocolate supplement guarantees weight loss, that affects equal pharmaceutical interventions in magnitude, that results occur without comprehensive lifestyle approaches, or that all individuals respond similarly regardless of metabolic differences.

The gap between “research shows cacao has metabolic effects” and “this supplement will help you lose weight” represents the uncertainty every consumer must acknowledge when evaluating products in this category.

Ceremonial-Grade vs. Conventional Processing: What the Distinction Means for Bioactive Compound Preservation

Understanding processing method differentiation helps consumers evaluate whether premium pricing for ceremonial-grade products represents genuine quality differences or merely marketing positioning.

The Conventional Chocolate Manufacturing Sequence

According to chocolate industry documentation, commercial chocolate production typically involves nine processing stages: high-temperature roasting (often 300-450°F, destroying heat-sensitive compounds), shell removal and nib extraction, grinding into chocolate liquor, alkaline treatment or Dutching (pH manipulation with potassium carbonate to reduce bitterness), pressing to separate cocoa butter and powder, conching (mixing at elevated temperatures for hours), addition of sugar/milk/fats, tempering and molding, and final packaging.

Each processing stage progressively reduces the bioactive compound profile that research associates with metabolic and satiety benefits. The alkaline treatment (Dutching) is particularly significant—while it improves flavor by reducing astringency and darkens color for consumer appeal, it substantially reduces flavanol content through pH manipulation.

Research examining this progressive degradation found that conventional chocolate processing substantially reduces bioactive compounds compared to minimally processed cacao. This explains why grocery store chocolate consumption doesn’t produce the outcomes observed in research studies using minimally processed cacao.

Ceremonial-Grade Processing Preservation Claims

According to Earth Echo Foods’ product positioning, Cacao Bliss uses sun-dried cacao processing that maintains compounds closer to raw cacao levels rather than high-heat roasting. The company positions this processing approach as preserving naturally occurring antioxidant content and bioactive compounds that conventional manufacturing reduces.

Sun-drying involves slow moisture removal at ambient temperatures (typically under 120°F) over extended periods rather than rapid high-heat roasting. This temperature control theoretically preserves heat-sensitive compounds like flavanols while still removing moisture necessary for shelf stability and food safety.

Consumer Verification Questions

When evaluating any chocolate-based supplement claiming superior processing, consumers should verify:

Does the company specifically disclose processing temperature ranges? Vague “low-heat” claims without numbers prevent verification. Does the company explain whether alkaline treatment (Dutching) is used? This detail significantly impacts compound preservation. Can the company provide third-party testing documentation confirming compound content? Claims require verification. How does the product’s antioxidant content compare to raw cacao baselines? Without comparative data, “ceremonial-grade” remains marketing language rather than verifiable differentiation.

Why This Processing Distinction Matters for Weight Management

The processing method question directly relates to weight management outcomes because the compounds potentially affected—flavanols, polyphenols, theobromine, and others—represent the same bioactive components examined in metabolic research. If conventional processing destroys substantial portions of these compounds, then conventional chocolate products would contain insufficient amounts to produce research-observed effects.

This provides theoretical justification for premium processing positioning: if research used minimally processed cacao and observed metabolic effects, then commercial products should preserve those compounds to align with research contexts. However, this logical framework doesn’t constitute proof that any specific product produces weight loss outcomes—it merely explains the rationale behind processing-focused positioning.

Safety Considerations and When to Consult Healthcare Providers

Before evaluating whether any chocolate-based supplement aligns with individual circumstances, consumers must understand safety parameters and situations requiring professional medical consultation.

General Safety Profile and Tolerance Considerations

Cacao-based supplements using quality ingredients are generally well-tolerated by most healthy adults when consumed at recommended dosages. However, several considerations warrant attention:

Stimulant Sensitivity: Cacao contains theobromine, a methylxanthine compound chemically related to caffeine but producing milder, longer-lasting effects. Individuals sensitive to any stimulant compounds—those who experience jitters from coffee, anxiety from green tea, or sleep disruption from afternoon caffeine—should evaluate tolerance carefully.

Digestive Response: Some individuals report mild digestive changes when introducing MCT oil, particularly if consuming higher amounts than their systems typically process. This usually resolves within several days as digestive systems adapt, but sensitive individuals may prefer gradual introduction.

Allergic Reactions: While rare, any food ingredient carries potential for allergic response in susceptible individuals. Consumers with known allergies to any listed ingredients should avoid the product entirely.

Medication Interactions Requiring Professional Consultation

Several situations require healthcare provider consultation BEFORE starting any chocolate-based supplement:

People who are pregnant or nursing, managing a medical condition, scheduled for a procedure, or taking prescription medications should ask a licensed clinician before using any supplement. If adverse reactions occur, stop use and seek medical advice.

Specific Considerations:

Blood Sugar Management: Cinnamon has documented effects on glucose metabolism. Individuals taking medications for blood sugar management should consult healthcare providers before supplementing with cinnamon-containing products.

Blood Thinners: Turmeric has mild blood-thinning properties. Individuals taking anticoagulant or antiplatelet medications should consult healthcare providers before adding turmeric supplementation.

Liver or Kidney Disease: Individuals with compromised liver or kidney function should consult healthcare providers before supplementing with concentrated compounds that require hepatic or renal processing.

Stimulant Sensitivity: Cacao contains theobromine, a methylxanthine compound. Individuals sensitive to stimulant compounds should evaluate tolerance carefully.

Medical Treatment Context

This analysis must emphasize clearly: Cacao Bliss is a dietary supplement, not a medical treatment. Consumers currently under medical care for metabolic conditions, cardiovascular health concerns, diabetes, or weight-related medical issues should NOT alter, reduce, or discontinue prescribed treatments based on supplement use.

Dietary supplements support overall wellness programs but cannot replace medical interventions when clinical care is indicated. Healthcare providers should supervise any modifications to medical treatment plans, and supplement use should be disclosed to all treating physicians to ensure comprehensive care coordination.

Supplement Category Limitations

Consumers should understand that dietary supplements cannot legally claim to treat, cure, or prevent diseases, function as nutritional support not pharmaceutical interventions, work optimally within comprehensive wellness programs, and require realistic expectations about outcome magnitude and timeframe.

Potential Side Effects and Adverse Reactions

While generally well-tolerated, possible reactions include digestive discomfort (rare, typically relates to MCT oil in sensitive individuals), stimulant effects (theobromine may cause mild wakefulness if consumed late evening), and allergic reactions (rare, but any food ingredient carries allergy potential).

Discontinue use and consult healthcare providers if adverse reactions occur.

Individual Response Variability

Even among healthy adults without contraindications, individual responses to any supplement vary dramatically based on genetic factors influencing nutrient metabolism, baseline metabolic rate and hormone levels, age and physiological changes (particularly perimenopause and menopause), current medication use even for unrelated conditions, overall dietary patterns and nutrient status, physical activity levels and types, sleep quality and duration, stress management and cortisol patterns, gut microbiome composition affecting nutrient absorption, and numerous other biochemical and lifestyle variables.

This variability explains why some consumers report substantial benefits while others experience minimal effects despite identical product use and similar starting circumstances. No supplement—regardless of ingredient quality or research foundation—produces uniform results across all individuals.

Questions Readers Often Consider Before Trying a Chocolate-Based Supplement

Rather than suggesting whether any product is a fit, this section lists common considerations readers discuss with clinicians and reflect on personally when evaluating chocolate-based weight management supplements.

Do I genuinely enjoy chocolate flavor enough for consistent daily consumption? Research-aligned usage patterns examined cacao consumption over 8-12 weeks minimum. Daily adherence requires authentic taste preference rather than forced compliance.

Am I prepared to integrate this into comprehensive lifestyle approaches? Research contexts examining cacao and weight loss included structured nutrition approaches and physical activity alongside cacao consumption, not supplement-only protocols.

What are my expectations regarding timeline and magnitude of results? Research studies typically measured outcomes at 8-12 week intervals with average reductions in the 5-7 pound range for participants following comprehensive programs. Individual responses vary dramatically.

Do I have any health conditions or take medications requiring consultation? Blood sugar medications, anticoagulants, and several other prescription categories may interact with supplement ingredients. Healthcare provider consultation remains essential before starting any supplement regimen.

Can I afford ongoing supplementation within my wellness budget? Premium processing methods and organic certification typically correlate with higher per-serving costs compared to conventional supplement categories. Long-term financial sustainability matters for consistent use.

Am I seeking dietary support or clinical-grade intervention? Research demonstrates cacao influences metabolic pathways, but individuals with BMI over 30 or significant health concerns should consult healthcare providers about appropriate intervention levels.

Do I understand that individual results vary substantially? Factors including age, baseline metabolic rate, hormonal status, medication use, genetic factors, sleep quality, stress levels, and numerous other variables create outcome unpredictability that no marketing can overcome.

Have I verified current company policies and ingredient specifications? All supplement companies can modify formulations, pricing, and policies. Independent verification of current terms protects against relying on outdated information.

How to Verify Company Claims, Current Terms, and Product Details

Independent verification protects consumers from relying exclusively on marketing claims or third-party interpretations. This section outlines verification methodology applicable to any supplement purchase decision.

Accessing Official Company Information

Earth Echo Foods maintains official contact channels that consumers can use to verify current policies, ingredient specifications, and company standing:

Phone: 1-888-997-3851 (Customer support line) Email: support@earthechofoods.com Physical Headquarters: Boulder, Colorado (Corporate location details available on company website)

The availability of multiple verifiable contact methods represents one indicator when evaluating company legitimacy. Quality supplement manufacturers typically provide accessible communication channels rather than hiding contact information.

What Current Information Consumers Should Verify Independently

Before making any supplement purchase decision, consumers should independently confirm the following details directly from official company sources, as all terms, pricing, and policies are subject to change without notice:

Current ingredient label specifications and amounts, processing method claims and third-party testing availability, posted company policies regarding returns and refunds, exact timeframes and conditions for any satisfaction guarantee offered, shipping timelines and costs and international availability if relevant, current promotional terms or pricing structures or discount availability.

This verification should occur at the time of potential purchase rather than relying on information from any analysis published previously, as supplement companies frequently modify terms, pricing, and promotional structures.

Company Legitimacy Evaluation Criteria

When evaluating any supplement company, consumers benefit from systematic assessment methodology:

Ingredient Disclosure Standards: Reputable companies provide complete ingredient lists with specific amounts. Proprietary blends that hide formulation details prevent consumers from evaluating dosage adequacy or comparing products across manufacturers.

Third-Party Testing Accessibility: Quality supplement companies typically conduct independent testing for purity, potency, and contaminant screening. Consumers can inquire whether certificates of analysis are available, though not all companies publish testing documentation publicly.

Return Policy Transparency: Legitimate operations clearly state return policies and refund procedures. Vague language or procedural obstacles to returns often indicate problematic business practices.

Marketing Language Assessment: Companies acknowledging individual outcome variability demonstrate regulatory awareness. Guaranteed weight loss claims or “works for everyone” language typically signals either regulatory ignorance or intentional deception.

Operational History Verification: Companies maintaining market presence over multiple years with verifiable customer bases demonstrate stability that newer operations may lack. Consumers can verify operational history through business registration databases and Better Business Bureau records.

Professional Credential Verification

When companies cite founder or formulator credentials, consumers can independently verify claims through professional networking platforms (LinkedIn), published work (books searchable through retailers and library systems), media appearances (entertainment news archives), and authenticated social media accounts. This verification process distinguishes accurate credentials from fabricated authority claims common in supplement marketing.

Verification Resources for Independent Confirmation

Consumers seeking to verify current company information, ingredient specifications, and posted policies can read more at Earth Echo Foods’ official Cacao Bliss product page where terms should be clearly stated and regularly updated. All pricing and company policies are subject to change and should be confirmed at the time of purchase consideration rather than relying on previously published information.

Frequently Asked Questions About Chocolate-Based Weight Management Supplements

What is Cacao Bliss and how is it different from regular cocoa powder?

Cacao Bliss is a dietary supplement formulated by Earth Echo Foods combining ceremonial-grade cacao with seven additional ingredients (cinnamon, turmeric, piperine, MCT oil, monk fruit, lucuma, Himalayan salt) positioned for synergistic metabolic support. According to the company, the primary difference from grocery store cocoa powder involves processing methods—ceremonial-grade cacao uses sun-drying and low-heat approaches to preserve bioactive compounds, while conventional cocoa powder typically undergoes high-heat roasting and alkaline treatment that research shows reduces antioxidant content substantially. Additionally, Cacao Bliss includes researched metabolic support compounds beyond base cacao.

Is Cacao Bliss FDA approved?

No, and this requires important context: Dietary supplements are not reviewed or approved by the FDA as finished products before market availability. The FDA’s regulatory approach to supplements differs fundamentally from prescription medications. Supplement manufacturers must ensure their products contain what labels claim and are free from contaminants, but the FDA does not evaluate whether supplements are effective or whether marketing claims are substantiated. This applies to all dietary supplements, not just Cacao Bliss specifically. The legally required disclaimer states: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”

Does chocolate actually increase GLP-1 levels?

Published research from the journal Nutrition (2020) demonstrated that cacao consumption nearly doubled GLP-1 hormone levels compared to water control groups in a 48-participant study. However, critical context: the study tested cacao-based beverages prepared for research purposes, not commercial products. It measured hormone response over hours, not long-term weight loss outcomes. The magnitude of GLP-1 enhancement differs substantially from prescription GLP-1 medications. Research demonstrates cacao can influence the same satiety hormone pathway targeted by medications, but through natural production enhancement at lower magnitudes rather than synthetic hormone delivery at therapeutic doses.

Can supplements like Cacao Bliss replace prescription GLP-1 medications?

No. While research shows dietary cacao influences GLP-1 production, the magnitude and mechanism differ substantially from pharmaceutical interventions. Prescription GLP-1 medications are drugs that mimic GLP-1 at therapeutic doses, producing pronounced appetite suppression under medical supervision for patients meeting specific clinical criteria. Dietary supplements support natural hormone function but cannot replicate pharmaceutical magnitude effects. Individuals currently prescribed GLP-1 medications should never alter, reduce, or discontinue prescribed treatments based on supplement use without physician guidance and supervision. These represent different categories with different applications.

How long does it take to see weight loss results from chocolate supplements?

Individual timelines vary dramatically based on baseline metabolic rate, age, hormonal status, consistency of use, comprehensive lifestyle factors, and numerous other variables. Research studies examining cacao and weight loss typically measured outcomes at 8-12 week intervals. Some individuals report reduced cravings and improved satiety within days, while scale changes typically emerge over weeks to months if they occur at all. Consumers should understand that supplements support comprehensive wellness programs—results depend on simultaneous attention to nutrition quality, physical activity, sleep adequacy, and stress management, not supplement consumption in isolation. No timeline can be guaranteed due to profound individual variability.

Are there any side effects or safety concerns with chocolate-based supplements?

Cacao-based supplements using quality ingredients are generally well-tolerated by healthy adults, but several considerations warrant attention. Cacao contains theobromine (a mild stimulant)—individuals sensitive to stimulants may experience jitters, anxiety, or sleep disruption if consumed late in the day. Some people report temporary digestive changes when introducing MCT oil. Turmeric has mild blood-thinning properties relevant for individuals taking anticoagulants or scheduled for surgeries. Cinnamon affects glucose metabolism, requiring consultation for individuals taking blood sugar medications. Allergic reactions, while rare, are possible with any food ingredient. Pregnant or nursing individuals should consult healthcare providers before using concentrated supplement formulations. Always disclose supplement use to treating physicians.

What makes ceremonial-grade cacao different from regular chocolate?

The distinction centers on processing methods and bioactive compound preservation. Ceremonial-grade cacao traditionally uses sun-drying at ambient temperatures (typically under 120°F) and minimal processing to preserve naturally occurring flavanols, polyphenols, and other compounds. Conventional chocolate manufacturing involves high-temperature roasting (often 300-450°F), alkaline treatment (Dutching), and extended processing that research shows reduces antioxidant content substantially compared to raw cacao. Research published in The Journal of Agricultural and Food Chemistry documented this progressive compound degradation through each processing stage. The ceremonial-grade positioning claims to maintain bioactive compounds at levels closer to raw cacao baselines, though consumers should verify specific products through third-party testing documentation rather than relying solely on marketing claims.

Is chocolate weight loss supplement use safe for people with diabetes?

This requires healthcare provider consultation before starting any supplement regimen. Several ingredients in chocolate-based formulations have documented effects on glucose metabolism—cinnamon influences blood sugar levels, and compounds in cacao affect insulin sensitivity. For individuals taking medications for blood sugar management, the combination may enhance medication effects and potentially require dosage adjustments under medical supervision to prevent hypoglycemia. Additionally, individuals with diabetes should verify carbohydrate and sugar content in any supplement consumed regularly. Never alter diabetes medication dosages based on supplement use without physician guidance. Healthcare providers should supervise integration of any supplements into diabetes management plans.

How do I know if a chocolate supplement company is legitimate or a scam?

Several legitimacy indicators help consumers differentiate quality companies from problematic operations. Verify these factors: transparent ingredient disclosure listing specific amounts rather than “proprietary blends” hiding formulation details; clear contact information including phone numbers, email addresses, and physical headquarters locations; adequate satisfaction guarantee windows (45-60+ days) allowing genuine evaluation time; realistic marketing language acknowledging individual variability rather than guaranteed outcome promises; third-party testing documentation availability for purity and potency verification; established operating history and verifiable customer base; founder credentials that can be independently confirmed through professional profiles and media appearances. Red flags include hidden contact information, very short or absent guarantee periods, extreme outcome promises, fake authority credentials, and pressure tactics creating false urgency.

Can I take chocolate supplements while pregnant or breastfeeding?

Healthcare providers should guide this decision. While dietary chocolate in moderate amounts is generally considered safe during pregnancy and lactation, concentrated supplement formulations containing multiple ingredients have not been adequately studied in pregnant or nursing populations. Insufficient safety data exists for ceremonial cacao supplementation during these life stages. Some ingredients like turmeric have traditional use restrictions during pregnancy in certain dosage ranges. The stimulant content from theobromine, while milder than caffeine, still warrants consideration. Conservative medical guidance typically recommends avoiding supplements without established safety profiles during pregnancy and nursing unless specific benefits outweigh unknown risks under healthcare provider supervision.

What’s the difference between taking a chocolate supplement and just eating dark chocolate?

Several distinctions matter: processing method differences affect bioactive compound content—ceremonial-grade supplements claim to preserve compounds that conventional chocolate manufacturing destroys through high-heat roasting and alkaline treatment. Research shows conventional dark chocolate retains only a portion of raw cacao’s antioxidant capacity. Caloric density differs substantially—chocolate supplements typically provide 30-50 calories per serving versus 150-200+ calories for equivalent flavor satisfaction from conventional chocolate bars. Sugar content varies dramatically—quality supplements use zero-calorie natural sweeteners like monk fruit, while conventional dark chocolate contains processed sugars even in high-percentage cacao bars. Additional ingredients in formulated supplements (cinnamon, turmeric, MCT oil) provide metabolic support compounds absent in plain chocolate. However, cost per serving also differs—supplements typically cost more than conventional chocolate on a per-serving basis.

Do I still need to diet and exercise if I’m taking a chocolate weight loss supplement?

Yes, absolutely. Research examining cacao and weight loss included comprehensive lifestyle protocols—participants followed structured nutrition plans and exercise programs alongside cacao consumption. Studies did not test supplement-only approaches divorced from other health behaviors. Supplements support wellness programs but cannot override poor lifestyle choices or compensate for inadequate nutrition, insufficient activity, poor sleep quality, or unmanaged stress. The research-aligned approach involves daily supplement use PLUS whole-food nutrition emphasis PLUS regular physical activity PLUS adequate sleep PLUS stress management practices. Consumers expecting significant weight loss from supplement consumption alone without lifestyle integration will likely experience disappointing outcomes. View supplements as supporting comprehensive approaches, not replacing fundamental health behaviors.

Source Information and Additional Resources

Primary Product Information:

For current ingredient labels, pricing details, company policies, and posted terms, consumers should review Earth Echo Foods’ official Cacao Bliss product page. Readers seeking to verify information presented in this analysis can access the official product page where complete disclosures should be available.

Company Contact Information:

Earth Echo Foods Boulder, Colorado Customer Support Phone: 1-888-997-3851 Customer Support Email: support@earthechofoods.com

(Readers should verify current contact details on official Earth Echo Foods pages.)

Research Citations Referenced in This Analysis:

This analysis referenced published research from multiple sources including studies published in the journal Nutrition (2020) examining GLP-1 hormone response to cacao consumption, research from the University of California San Diego School of Medicine examining weight loss outcomes with cacao protocols, studies from Cairo University examining cinnamon’s influence on glucose metabolism, research from the State University of New York School of Medicine exploring curcumin’s potential effects on adipose inflammation, studies from Columbia University and King’s College London examining MCT oil’s influence on satiety hormones, and research published in The Journal of Agricultural and Food Chemistry documenting compound degradation through conventional chocolate processing.

Consumers interested in examining original research should search academic databases using author names, institution affiliations, and publication details to access primary sources rather than relying exclusively on summaries or marketing interpretations.

Independent Verification Resources:

For consumers seeking to verify supplement quality claims independently:

ConsumerLab.com provides independent testing results for supplements, including product quality verification and label accuracy assessment (subscription required for full access).

Labdoor offers independent supplement testing and quality grading based on label accuracy, nutritional value, ingredient safety, and projected efficacy.

NSF International and USP (United States Pharmacopeia) provide third-party certification programs for supplements meeting specific quality and purity standards (consumers can search certified product databases).

National Institutes of Health Office of Dietary Supplements provides evidence-based information about dietary supplement ingredients, safety considerations, and research contexts at ods.od.nih.gov.

Disclaimers

Editorial Disclaimer: This consumer analysis is for informational purposes only and does not constitute medical advice, diagnosis, treatment recommendations, or professional health guidance. Weight management concerns should be evaluated by qualified healthcare professionals. Always consult a qualified healthcare professional before starting any new supplement regimen, particularly if taking medications, managing existing health conditions, or if pregnant or nursing. This analysis does not evaluate clinical efficacy or determine which products are objectively “best” as individual needs vary.

Dietary Supplement Notice: Cacao Bliss is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Dietary supplements are not reviewed or approved by the FDA as finished products before market availability.

Results May Vary: Individual weight loss results vary significantly based on factors including age, baseline health condition, metabolic rate, hormonal status, consistency of use, genetic factors, current medications, physical activity levels, overall dietary patterns, sleep quality, stress management, and numerous other individual variables. While some consumers report weight management benefits, results are not guaranteed. Research findings from controlled studies may not translate directly to individual supplement use in uncontrolled real-world conditions.

Professional Medical Disclaimer: This analysis is educational and does not constitute medical advice or professional health guidance. Cacao Bliss is a dietary supplement, not a medication or medical treatment. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting Cacao Bliss or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval. Healthcare providers should supervise any modifications to medical treatment plans.

Medication Interaction Considerations: Individuals taking medications for blood sugar management should exercise particular caution, as cinnamon’s documented effects on glucose metabolism may necessitate medication dosage adjustments under healthcare provider supervision. Individuals taking blood thinners or anticoagulants should consult healthcare providers before supplementing with turmeric due to mild blood-thinning properties.

Affiliate Disclosure: This article contains affiliate links. If purchases are made through these links, commissions may be earned at no additional cost to consumers. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research, publicly available company information, and established evaluation criteria.

Pricing and Terms Disclaimer: All prices, discounts, guarantee terms, and promotional offers mentioned were accurate at the time of publication (January 2, 2026) but are subject to change without notice. Always verify current pricing, terms, policies, and promotional offers on official Earth Echo Foods channels before making purchase decisions. This analysis does not guarantee current availability or specific pricing.

Publisher Responsibility Disclaimer: The publisher of this analysis has made every effort to ensure accuracy at the time of publication based on available research, company materials, and industry standards. We do not accept responsibility for errors, omissions, or outcomes resulting from use of the information provided. Consumers are encouraged to verify all details directly with Earth Echo Foods and their healthcare providers before making decisions.

Research Context Disclaimer: Research studies cited examine cacao compounds, minimally processed cacao consumption, or specific ingredient effects in controlled settings. Study results do not guarantee identical outcomes with supplement use. Research contexts differ from real-world application in numerous ways including dosage standardization, participant selection criteria, controlled environments, comprehensive monitoring, and defined study durations. Individual supplement responses vary and may differ substantially from research findings. No research cited specifically evaluated Earth Echo Foods’ Cacao Bliss product.

Contact Information Disclaimer: All contact information, policies, shipping terms, satisfaction guarantees, and company details were accurate as of January 2, 2026 publication date but remain subject to change without notice. Consumers should verify current information on official company channels before purchasing or seeking support.

Testimonial and Customer Experience Disclaimer: Any customer testimonials or reported experiences referenced represent individual outcomes and are not typical results. Individuals providing testimonials may have received free products or compensation in exchange for honest reviews. Results vary based on numerous individual factors. Testimonials reflect opinions of specific customers and do not represent guarantees of similar outcomes for all consumers.

Regulatory Context Disclaimer: The dietary supplement industry faces ongoing regulatory discussion and oversight evolution. Consumers should understand that supplements receive less stringent pre-market oversight than pharmaceutical products. Reputable companies invest in third-party testing, transparent sourcing, and quality manufacturing practices, but verification remains the consumer’s responsibility.

For personalized guidance on weight management strategies, metabolic health optimization, dietary supplement evaluation, or comprehensive wellness program development, consumers should consult qualified healthcare professionals, registered dietitians, or certified wellness practitioners who can provide individualized recommendations based on complete health histories, current medications, and specific goals.

Contact: Earth Echo Foods Email: support@earthechofoods.com Phone: 1-888-997-3851 (Readers should verify current contact details on official Earth Echo Foods pages.)

This is a consumer analysis summarizing publicly available information for informational purposes only. This consumer analysis was published January 2, 2026, and reflects information accurate as of that date. All research citations, company claims, and policy details should be independently verified on current official sources before making purchasing decisions.

CONTACT: Email: support@earthechofoods.com 
Phone: 1-888-997-3851

Clínica García-Dihinx Celebrates 500 Google Reviews Milestone, Reinforcing Its Role as a Leading Plastic Surgery Clinic in Zaragoza, Spain

Clínica García-Dihinx Celebrates 500 Google Reviews Milestone, Reinforcing Its Role as a Leading Plastic Surgery Clinic in Zaragoza, Spain




Clínica García-Dihinx Celebrates 500 Google Reviews Milestone, Reinforcing Its Role as a Leading Plastic Surgery Clinic in Zaragoza, Spain

Clinic’s consistent 4.7-star rating reflects nearly four decades of patient trust, care quality, and international recognition in the field of aesthetic surgery

Zaragoza, Aragón, Jan. 02, 2026 (GLOBE NEWSWIRE) — Clínica García-Dihinx, a leading plastic surgery clinic in Zaragoza, Spain, is proud to announce that it has reached a new milestone: more than 500 public reviews on Google Maps, maintaining a strong average rating of 4.7 out of 5. This accomplishment is a reflection of nearly 40 years of sustained dedication to patient care, surgical excellence, and personalized treatment experiences.

Clínica García-Dihinx Celebrates 500 Google Reviews Milestone, Reinforcing Its Role as a Leading Plastic Surgery Clinic in Zaragoza, Spain

Plastic surgery clinic in Zaragoza, Spain offering aesthetic and reconstructive procedures to local and international patients.

The milestone comes at a time when online reviews play a decisive role in how patients select medical providers—especially for international patients considering aesthetic procedures in Spain. The clinic’s verified reputation through public feedback reinforces its position as a trusted and highly rated provider in the field of cosmetic and reconstructive surgery.

“This is more than a number—it’s a recognition of the relationships we’ve built with patients over decades,” said Dr. García-Dihinx, medical director of the clinic. “Every review tells part of a real experience, and we value each one as part of our ongoing commitment to quality, transparency, and patient safety.”

Founded more than 38 years ago, Clínica García-Dihinx has continuously evolved to meet the expectations of a diverse and international patient base. The clinic offers a wide range of aesthetic and reconstructive treatments performed by a multidisciplinary medical team with expertise in modern, minimally invasive, and patient-tailored surgical methods. Its focus on ethical medical practice, post-surgical follow-up, and clear communication has earned the trust of thousands of patients over the years.

Among the most commonly cited aspects in patient reviews are:

  • The professionalism and empathy of the medical team
  • High standards of surgical care and hygiene
  • Attention to individual goals and expectations
  • Clear pre- and post-operative communication
  • Consistent outcomes with natural aesthetic results

The clinic’s visibility and reliability among both local and international audiences are supported by its official online presence. Visitors to garcia-dihinx.com can access detailed information about procedures, medical protocols, safety standards, and real patient stories. In addition, educational material and behind-the-scenes content are available on the clinic’s YouTube channel.

“Transparency and continuous improvement are core values here,” added the clinic’s management team. “By listening to patient feedback, we’ve been able to refine protocols and maintain high satisfaction rates. Our reviews help guide us in improving not just results, but also the overall experience.”

As the demand for medical tourism in Spain continues to rise, particularly in plastic surgery, patients are turning to trusted sources like Google to validate their options. The clinic’s consistent stream of verified, detailed, and positive reviews offers a reliable resource for those exploring surgery abroad.

With this 500-review milestone, Clínica García-Dihinx reaffirms its ongoing mission to provide a safe, ethical, and results-driven approach to plastic surgery, while remaining accessible and transparent to both local residents and international visitors.

For more information about treatments, medical team profiles, or to read patient testimonials, visit garcia-dihinx.com or view the clinic’s public profile on Google Maps.

Clínica García-Dihinx Celebrates 500 Google Reviews Milestone, Reinforcing Its Role as a Leading Plastic Surgery Clinic in Zaragoza, Spain

Clinic specializing in cosmetic surgery and patient-focused treatments, with a reputation for quality care in Spain.

About Clínica García-Dihinx

Clínica García-Dihinx is a plastic surgery clinic in Zaragoza, Spain, specializing in aesthetic and reconstructive procedures. With over 38 years of experience, the clinic is recognized for its commitment to ethical medical practice, personalized care, and surgical excellence.

Press Inquiries

Clínica García-Dihinx
https://garcia-dihinx.com/
Guillermo Suils
prensa@garcia-dihinx.com
+34 657 53 34 14

A video accompanying this announcement is available here: https://youtube.com/watch?v=jntsvuEyyVg

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules




Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or pre-funded warrant) and associated Series K-1warrants and Series K-2 warrants, for expected gross proceeds to INBS of approximately $10.0 million, before deducting placement agent fees and other offering expenses payable by the Company. The Series K-1warrants and Series K-2 warrants will have an exercise price of $4.10 per share of common stock and will be exercisable immediately upon issuance. The Series K-1 warrants and Series K-2 warrants will each have a term of five years following the date a registration statement registering all warrant shares underlying the Series K-1 warrants and Series K-2 warrants is declared effective by the United States Securities and Exchange Commission (the “SEC”).

Harry Simeonidis, President and CEO of INBS, commented, “We welcome the continued support from our investors as we intend to use the proceeds of this private placement for working capital and general corporate purposes, including funding our 510(k) submission with the FDA for our non-invasive Intelligent Fingerprinting Drug Screening System and furthering our international market expansion.”

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the private placement.

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file an initial registration statement with the SEC covering the resale of the shares of common stock issued to the investors (including the shares of common stock issuable upon the exercise of the warrants) no later than 10 calendar days following the date of the agreement and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 45 days after the date of such agreement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. 

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: http://www.ibs.inc/.

Forward-Looking Statements:

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s intended use of proceeds from the private placement, ability to develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:

Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026




Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations Corporate Communications
Ryan Crowe Christina Chan
914.847.8790 914.847.8827
ryan.crowe@regeneron.com christina.chan@regeneron.com

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)




Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.

The Company granted options to purchase 312,000 shares, in the aggregate, of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to $40.40, which was the closing price of Terns’ common stock on December 31, 2025. The options vest over four years, subject to the employees’ continued service through the applicable vesting dates.

About Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program, TERN-701, is a highly selective, oral, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
CG Life
media@ternspharma.com

GH Research to Announce IND Status for GH001

GH Research to Announce IND Status for GH001




GH Research to Announce IND Status for GH001

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST.

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.

About GH001

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), we believe that GH001 has the potential to change the way TRD is treated today.

Investor Relations:
Julie Ryan
GH Research PLC
investors@ghres.com

Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held on February 26

Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held on February 26




Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held on February 26

CINCINNATI, Jan. 02, 2026 (GLOBE NEWSWIRE) — Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2025, on Wednesday, February 25, 2026, following the close of trading on the New York Stock Exchange.

Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, February 26, 2026, to discuss the company’s quarterly results and to provide an update on its business.

Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/srzsz65g.

Participants may also register via teleconference at https://register-conf.media-server.com/register/BIe4160b0d86fb4a3cb11588d64e00d9e7.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call’s conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation’s largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed’s future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT:
Michael D. Witzeman
(513) 762-6714        

Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success

Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success




Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success

Winnipeg, Manitoba, Jan. 02, 2026 (GLOBE NEWSWIRE) —

Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success

Mint Ops Logo

FOR IMMEDIATE RELEASE 

Winnipeg, MB – January 2nd, 2026 – Mint Ops, a national ecosystem of services supporting dental clinics across Canada, today announced the official launch of its fifth Division: Transition Consulting, a new division designed to help dental clinic owners navigate practice transitions, strategic growth, and long-term operational success. 

Transition Consulting expands Mint Ops’ ecosystem beyond software, staffing, marketing, imaging, and remote administration by introducing non-broker consulting services focused on practice transitions and operational strategy. The division supports dentists through major decisions including buying or selling a clinic, strengthening operations, increasing clinic value, and planning long-term growth. 

“Dentistry is changing fast, and clinic owners are being forced to make bigger decisions earlier than ever,” said Alex Zlatin, CEO of Mint Ops. “Transition Consulting exists to give owners clear, practical guidance – backed by real data, operational insight, and an ecosystem that can actually execute the plan.” 

To lead the new division, Mint Ops welcomes Dr. Dev Mangat, a dentist with extensive experience supporting clinic transitions and operational strategy across Canada. Dr. Mangat brings both clinical and advisory expertise to guide owners through complex and often emotional business decisions. 

“Clinic ownership is one of the most significant personal and financial investments a dentist will ever make,” said Dr. Mangat. “Transition Consulting provides owners with grounded, unbiased support – whether they are preparing to sell, planning to expand, or simply trying to run a better clinic.” 

Transition Consulting integrates directly into the broader Mint Ops ecosystem, which includes: 

  • Practice Software and next-generation platforms currently in development, with previews planned at major industry shows in 2026 
  • Grayscale Imaging, compatible with all TWAIN sensors, cameras and PMSs 
  • Remote Administration, acting as an extension of front desk teams through outbound patient and insurance outreach 
  • Recruitment Services, placing staff in both urban and remote communities across Canada 
  • Marketing & Digital Services, including affordable subscription-based websites and fully transparent campaign reporting 

This launch marks a natural evolution of Mint Ops’ long-term mission to support dental clinics at every stage of ownership – from growth and operations to transition and succession planning. 

For more information about Transition Consulting, visit www.mintops.ca or contact: 

Media Contact 

Alex Zlatin 

CEO, Mint Ops 

Email: info@mintops.ca 

 

Mint Ops Launches Its Fifth Division: Transition Consulting to Support Dental Clinic Owners Through Growth, Buy/Sell Decisions, and Operational Success

Mint Ops Logo

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel




Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company’s litigation and intellectual property counsel.

Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the Company continues to advance and protect its proprietary pharmaceutical assets and development pipeline. Mr. Kasowitz is a highly experienced U.S. trial lawyer with decades of experience leading high-stakes intellectual property and complex commercial litigation in federal and state courts. His background includes representation in intellectual property disputes involving innovative technologies and life sciences.

Marc E. Kasowitz is a veteran American trial lawyer and the founding managing partner of Kasowitz LLP, a New York-based litigation firm he co-founded in 1993. He is widely recognized for his expertise in complex commercial litigation, having been named among the country’s top trial lawyers by Benchmark Litigation and honored as a Litigation Trailblazer by the National Law Journal. Mr. Kasowitz regularly serves as lead counsel in high-stakes disputes involving antitrust, securities, banking, and product liability matters, representing major corporate clients across a range of industries, and has earned recognition from Chambers USA, The Legal 500, and other legal ranking organizations for his trial experience and advocacy. For more information, click Kasowitz LLP

“Protecting and enforcing our intellectual property portfolio is central to Scilex’s long-term strategy and shareholder value,” said a spokesperson for Scilex. “The appointment of Marc Kasowitz and Kasowitz LLP strengthens our legal capabilities as we continue to commercialize our products and advance our late-stage pipeline.”

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Scilex’s intellectual property goals and processes, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2026 Scilex Holding Company All Rights Reserved.

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy




CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

Engagement reinforces CDT’s strategy to unlock value from its solid-form asset portfolio

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has engaged NJS Foresight Bio-Advisory, LLC to identify, source and support the execution of out-licensing opportunities for selected assets within its solid-form patent portfolio. The engagement is intended to expand CDT’s commercial reach and accelerate potential licensing and royalty-based transactions.

NJS Foresight Bio-Advisory, LLC brings more than 20 years of out-licensing experience and has completed numerous successful licensing agreements across the biotechnology and pharmaceutical sectors. The firm’s principal, Dr. Nicholas J. Sarlis, brings over 25 years of clinical and pharmaceutical/biotechnology expertise to the role, including leadership of multidisciplinary teams advancing early and late-stage development programs, involvement in the successful launch of six global products, and direct participation in more than thirty clinical studies. He holds medical and doctoral degrees from the University of Athens and a PhD from Imperial College London, and is board certified in Internal Medicine in the United States. He is a Fellow of both the American College of Physicians and the Royal Society of Medicine.

CDT has built a portfolio of solid-form patents including cocrystals and salts that deliver enhanced physicochemical properties such as improved solubility, bioavailability and alternative delivery modes. These solid-forms also carry up to twenty years of patent protection, creating a pathway for partners to extend product lifecycles beyond traditional patent expiry.

The Company has been actively reviewing opportunities where marketed products face significant patent cliffs and where CDT has developed differentiated solid-forms of these active pharmaceutical ingredients. Industry data indicates a renewed period of investment activity in biopharma as companies respond to patent expirations, strategic consolidation and the adoption of AI-driven technologies. CDT believes these trends create a constructive environment for solid-form innovation and out-licensing.

“CDT continues to assess commercial pathways for its portfolio and sees strong potential for its solid-form assets to support lifecycle management strategies across the sector,” said Dr. Andrew Regan, Chief Executive Officer of CDT.

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. In parallel, CDT has implemented a cryptocurrency treasury reserve strategy, initially focused on Bitcoin (BTC), designed to diversify its capital allocation and strengthen its financial position. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com